Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
22.66
0.00 (0.00%)
Mar 27, 2026, 4:00 PM EDT - Market closed
Innoviva Employees
Innoviva had 159 employees as of December 31, 2025. The number of employees increased by 32 or 25.20% compared to the previous year.
Employees
159
Change (1Y)
32
Growth (1Y)
25.20%
Revenue / Employee
$2,586,969
Profits / Employee
$1,705,440
Market Cap
1.68B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| Agios Pharmaceuticals | 540 |
| Ocular Therapeutix | 325 |
| Zymeworks | 264 |
| Capricor Therapeutics | 231 |
| Relay Therapeutics | 192 |
| Soleno Therapeutics | 182 |
| Definium Therapeutics | 106 |
INVA News
- 20 days ago - Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report - Business Wire
- 4 weeks ago - Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript - Seeking Alpha
- 4 weeks ago - Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress - Business Wire
- 5 weeks ago - Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Business Wire
- 3 months ago - U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents - Business Wire
- 3 months ago - US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections - Reuters
- 3 months ago - Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea - Business Wire
- 4 months ago - Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference - Business Wire